Harvard Bioscience Names Ronald Aplin to Vice President Global Operations and Quality

25 Years of Industry Experience Adds Strength to Executive Management Team

HOLLISTON, Mass., March 10, 2014 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has named Ronald Aplin to Vice President Global Operations and Quality, effective immediately. This is a newly created position.

Mr. Aplin has more than 25 years experience in operations and supply chain management. He comes to Harvard Bioscience from Corning Incorporated, where he served as Operations/Plant Manager since 2012. Prior to Corning, he worked as Director of Operations at Becton, Dickinson and Company. Earlier, he served as Plant Manager at Teleflex Medical, as well as senior operational roles in the petrochemical industry. He holds a bachelor's degree from the University of South Alabama and a master of arts degree in organizational management from the University of Phoenix.

Mr. Aplin said, "During my two and a half decades serving various medical customer bases, I have become keenly aware of the importance of continuous improvement and innovative approaches to an ever-changing global environment. I am convinced that Harvard Bioscience is well positioned for growth as the Company seeks to expand its footprint in international markets, while it continues the product development that has cemented its 113-year-old reputation for excellence. I look forward to working with Company management as we expand our global operations."

Jeffrey A. Duchemin, CEO and President of Harvard Bioscience, said, "Recruiting Ron Aplin as our first Vice President Global Operations and Quality is a significant win for Harvard Bioscience. His appointment continues our drive to bolster our executive management team with highly regarded leaders in the life science research industry. Ron's new position is another example of Harvard Bioscience becoming a more functional organization, as we continue to drive efficiencies to improve our operational structure. We are grateful that Ron decided to join us, and we expect to benefit from his expertise and leadership as we seek to expand our global presence in the months and years ahead."

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer, and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research. Our products are sold to thousands of researchers in over 100 countries primarily through our 850 page catalog (and various other specialty catalogs), our website, through distributors, including GE Healthcare, Thermo Fisher Scientific, and VWR, and via our field sales organization. Harvard Bioscience has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, and Spain with additional facilities in France and Canada. For more information, please visit our website at www.harvardbioscience.com.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the anticipated savings, cost reductions, restructuring charges and reinvestment amounts. These statements involve risks and uncertainties, including among other things, market conditions and other factors that may cause the actual results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Bioscience expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

The Harvard Bioscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6426

For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site.

Harvard Bioscience
Jeffrey A. Duchemin
President and Chief Executive Officer
Tel: (508) 893-8999

Investor and Public Relations:
Dian Griesel Inc.
Cheryl Schneider/Susan Forman
(212) 825-3210
- See more at: http://www.globenewswire.com/news-release/2014/03/10/616970/10071748/en/Harvard-Bioscience-Names-Ronald-Aplin-to-Vice-President-Global-Operations-and-Quality.html#sthash.NhEg0w4X.dpuf